Almirall reports satisfaction with 2012 business performance

Almirall has published its financial results for 2012, during which it was able to meet its targets and lay the foundations for an anticipated period of strong growth.

The company's revenues for the year came to 900.2 million euros (788.15 million pounds), which was up by 3.1 percent on 2011, despite a dip in sales associated with Spanish healthcare reforms and increased generic competition.

During the year, the firm earned 217.3 million euros in non-sales-related income thanks to the booking of milestones mainly associated with the US and EU approval of aclidinium monotherapy, its promising new therapy for chronic obstructive pulmonary disease.

Thanks to the expansion of this product and Sativex, plus the recent EU approval of Constella for irritable bowel syndrome with constipation, Almirall will be carrying out more than 30 product launches in 2013.

Eduardo Sanchiz, chief executive officer at Almirall, said: "We look forward to 2013 as an inflexion year and a year of strong product launch execution."

The company is headquartered in Barcelona and employs more than 2,800 people across the world.